Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors
暂无分享,去创建一个
A. Avilés-Salas | O. Arrieta | A. L. Colín-González | N. Hernández-Pedro | Pedro Barrios-Bernal | M. Orozco-Morales | G. Cruz-Rico | Dr. Rodrigo Catalan | Elsa Dosal-Mancilla | P. Barrios-Bernal
[1] O. Arrieta,et al. CD47-SIRPα Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer , 2020, Journal of immunology research.
[2] F. Hirsch,et al. Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution , 2020, Molecular oncology.
[3] Jianguo Xu,et al. CD47: the next checkpoint target for cancer immunotherapy. , 2020, Critical reviews in oncology/hematology.
[4] Caicun Zhou,et al. Immunotherapy as a treatment for small cell lung cancer: a case report and brief review , 2020, Translational lung cancer research.
[5] A. Ricci,et al. Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia , 2020, Cancers.
[6] A. Akarca,et al. Programmed Cell Death Ligand Expression Drives Immune Tolerogenesis across the Diverse Subtypes of Neuroendocrine Tumours , 2020, Neuroendocrinology.
[7] A. Cardona,et al. Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non‐small cell lung cancer , 2020, Cancer medicine.
[8] M. Triggiani,et al. Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC , 2020, Frontiers in Immunology.
[9] G. Pelosi,et al. The utility of Ki-67 as a prognostic biomarker in pulmonary neuroendocrine tumours: protocol for a systematic review and meta-analysis , 2019, BMJ Open.
[10] Chuang Chen,et al. High expression of CD47 in triple negative breast cancer is associated with epithelial-mesenchymal transition and poor prognosis , 2019, Oncology letters.
[11] M. Ladanyi,et al. Stage IV Lung Carcinoids: Spectrum and Evolution of Proliferation Rate, Focusing on Variants with Elevated Proliferation Indices , 2019, Modern Pathology.
[12] I. Weissman,et al. CD47 Blockade by Hu5F9‐G4 and Rituximab in Non‐Hodgkin's Lymphoma , 2018, The New England journal of medicine.
[13] M. Dietel,et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal , 2018, Modern Pathology.
[14] J. Parsons,et al. CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer , 2017, Clinical Cancer Research.
[15] G. Pelosi,et al. Classification of pulmonary neuroendocrine tumors: new insights. , 2017, Translational lung cancer research.
[16] Xianglin Yuan,et al. Thrombospondin-1 is a multifaceted player in tumor progression. , 2017, Oncotarget.
[17] Lin F. Yang,et al. Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells , 2017, Front. Immunol..
[18] Lu Gao,et al. Thrombospondin-1 signaling through CD47 inhibits cell cycle progression and induces senescence in endothelial cells , 2016, Cell Death and Disease.
[19] Zhijie Kang,et al. CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer , 2016, Scientific Reports.
[20] I. Weissman,et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. , 2016, The Journal of clinical investigation.
[21] Lu Gao,et al. CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis , 2016, Oncotarget.
[22] P. Sharma,et al. The future of immune checkpoint therapy , 2015, Science.
[23] W. Travis,et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] W. Travis. Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine. , 2014, Thoracic surgery clinics.
[25] W. Travis,et al. Ki-67 Antigen in Lung Neuroendocrine Tumors: Unraveling a Role in Clinical Practice , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[26] L. Martiny,et al. CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest , 2012, British journal of pharmacology.
[27] I. Weissman,et al. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells , 2012, Leukemia.
[28] I. Weissman,et al. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. , 2011, Blood.
[29] D. Roberts,et al. Thrombospondin-1 Inhibits VEGF Receptor-2 Signaling by Disrupting Its Association with CD47* , 2010, The Journal of Biological Chemistry.
[30] D. Roberts,et al. Treatment of liver ischemia-reperfusion injury by limiting thrombospondin-1/CD47 signaling. , 2008, Surgery.
[31] G. Fortin,et al. CD47 in the immune response: role of thrombospondin and SIRP-alpha reverse signaling. , 2008, Current drug targets.
[32] Julia Fukuyama,et al. Thrombospondin-1 Inhibits Nitric Oxide Signaling via CD36 by Inhibiting Myristic Acid Uptake* , 2007, Journal of Biological Chemistry.
[33] D. Ettinger. Overview and state of the art in the management of lung cancer. , 2004, Oncology.
[34] Partha Pratim Manna,et al. CD47 Mediates Killing of Breast Tumor Cells via Gi-Dependent Inhibition of Protein Kinase A , 2004, Cancer Research.
[35] N. Pedersen,et al. Transcriptional gene expression profiling of small cell lung cancer cells. , 2003, Cancer research.
[36] Z. Baloch,et al. Neuroendocrine tumors of the thyroid gland. , 2001, American journal of clinical pathology.
[37] H. Krutzsch,et al. Thrombospondin-1 promotes alpha3beta1 integrin-mediated adhesion and neurite-like outgrowth and inhibits proliferation of small cell lung carcinoma cells. , 2000, Cancer research.
[38] M. Sarfati,et al. Dendritic Cells Production and Maturation of Human CD47 Engagement Inhibits Cytokine , 2000 .